Good news for travellers that Covishield recognised by 16 Europan nations, says SII’s Adar Poonawalla \
2 min read
\
\

Good news for travellers that Covishield recognised by 16 Europan nations, says SII’s Adar Poonawalla

17-Jul-2021
New Delhi [India], July 17 (ANI): Chief Executive Officer (CEO) and owner of the Serum Institute of India (SII) on Saturday said he it was good news that Covishield, the Indian version of the 16 European countries now recognised and accepted Oxford-Astrazeneca vaccine for entry of international travellers.
17-Jul-2021 World
\
RDIF, SII to start production of Sputnik V COVID-19 vaccine in India from September \
3 min read
\
\

RDIF, SII to start production of Sputnik V COVID-19 vaccine in India from September

13-Jul-2021
New Delhi [India], July 13 (ANI): The Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, and Serum Institute of India (SII), announced cooperation to produce in India the Russian Sputnik vaccine against coronavirus.
13-Jul-2021 Coronavirus
\
Switzerland, Iceland, 7 EU nations okay SII’s Covishield vaccine, day after India’s request \
5 min read
\
\

Switzerland, Iceland, 7 EU nations okay SII’s Covishield vaccine, day after India’s request

01-Jul-2021
Zurich [Switzerland], July 1 (ANI): A day after external affairs minister S Jaishankar said he has taken up with European Union to accept COVID-19 vaccines, such as Covishield and Covaxin, for Indian nationals travelling to Europe, Switzerland, Iceland and seven European Union countries on Thursday allowed the Serum Institute-manufactured Oxford-Astrazeneca vaccine.
01-Jul-2021 Coronavirus
\
Novavax’s vaccine, also produced by SII, found 90 pc effective against COVID-19 variants \
2 min read
\
\

Novavax’s vaccine, also produced by SII, found 90 pc effective against COVID-19 variants

14-Jun-2021
New Delhi [India], June 14 (ANI): US Biotechnology company Novavax on Monday announced that its Covid-19 vaccine provides 100 per cent protection against moderate and severe symptoms of the disease and 90.4 per cent efficacy overall in phase 3 trials.
14-Jun-2021 Coronavirus
\
UP man alleges no antibodies developed post vaccine, lodges complaint against SII CEO, ICMR chief \
3 min read
\
\

UP man alleges no antibodies developed post vaccine, lodges complaint against SII CEO, ICMR chief

01-Jun-2021
Lucknow (Uttar Pradesh) [India], June 1 (ANI): A man in Uttar Pradesh's Lucknow has filed a complaint against Serum Institute of India (SII) CEO Adar Poonawala and Dr. Balram Bhargava, head of the Indian Council of Medical Research (ICMR) after he alleged that no antibodies were formed in his body after receiving the first dose of Covishield.
01-Jun-2021 National
\